Encorium Group names new CEO

In addition to assuming overall management of the company and its European operations, Mr Ginsberg will assume responsibility of North American operations from Kenneth Borow, who is no longer an employee of the company.

Mr Ginsberg brings to Encorium over 25 years of executive experience within the biopharmaceutical industry. Most recently he was the vice president of medical affairs and clinical affairs for KV Pharmaceuticals. Previously he was the chief medical officer and senior vice president of Omnicare Clinical Research and CEO and president of Omnicomm Systems.

Mr Lindevall said: “The appointment of David as the Company’s president and CEO is an exciting and positive step forward for Encorium. David’s substantial experience and knowledge of the clinical research industry will be invaluable to the expansion of the company’s core business. The addition of David to the senior management team will also allow me to focus more intently on the company’s strategic growth plan.”

The company also announced two changes to its board of directors, appointing David Morra effective immediately and appointing a current director of Prologue Research International with executive level healthcare management experience to be effective upon the closing of the acquisition of Prologue.

The newly appointed directors will replace Scott Jenkins and Christopher Meshginpoosh, who have tendered their resignation from the company’s board of directors, effective immediately. With these changes, Encorium’s board of directors will remain at five members and will consist of a majority of independent directors.